Uterine Fibroids Treatment Market

Rising incidences of uterine fibroids is major factor for raising the market growth

Uterine fibroids are the most common pelvic tumors in women, occurring globally, with 21.4% prevalence. About 20 percent to 80 percent of women develop fibroids by the time they reach age 50. Fibroids are most common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50.

The increasing female aging population is propelling the market's growth as the elderly population is more susceptible to gynecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand of the global fibroid treatment market. National Women’s Health Network in the year 2015 reported that African-American women are two to three times more likely to develop fibroids than women of other races.

According to the National Cancer Institute, 2015, an estimated 727,200 women were living with uterine cancer in the United States, which supports the growth of uterine fibroid treatment.

In the United States, every year, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing days of work due to fibroid symptoms.

Women with fibroids waited an average of 3.6 years to seek treatment.

In the UK, the uterine fibroid was diagnosed in 30,929 people at NHS hospital by hospital consultants in 2012 – 2013, which is expected to drive the uterine fibroid treatment devices market growth. 

According to the National Uterine Fibroids Foundation, in 2010, an estimated 12 hysterectomies were performed in the U.S. every 10 minutes. Around 600,000 hysterectomies were performed annually in the U.S., out of which around 170,000 – 300,000 were performed due to uterine fibroids, which is expected to support the growth of the uterine fibroid treatment market shortly. According to the Centers for Disease Control and Prevention (CDC), in the U.S., around 53,028 women were diagnosed with uterine cancer in 2014, which supports the growth of uterine fibroid treatment. 

Growing awareness about uterine fibroids among the female population would help in market growth. Raising awareness about uterine fibroids and recognizing July as Uterine Fibroids Awareness Month can help spark more conversations about menstrual issues and lessen the taboo around these topics, encouraging more women to talk to their health care providers and strengthening the call for increased investment in research and better treatments. In July 2018, Acessa Health Inc., developer of the Acessa System®, has honored Uterine Fibroid Awareness Month by partnering with The White Dress Project, a nonprofit group that promotes fibroid awareness advocacy, to launch the Goodbye Fibroids initiative. Goodbye Fibroids will provide a forum for women to share their stories, learn about treatment options and patient-doctor discussions, and unite to raise awareness to elevate the standard of care for uterine fibroids.

In February 2018, CARE (Community, Action, Research, and Education) About Fibroids, a recently-formed nonprofit women’s health organization dedicated to increasing awareness of uterine fibroids, today unveiled a patient-centered online resource to help educate and inform patients about uterine fibroids. The website, www.CAREaboutFibroids.org, serves as a one-stop-shop for the “411” on uterine fibroids, as well as a compilation of resources and published studies on fibroids. CARE About Fibroids believes that awareness will help more women get an earlier diagnosis of uterine fibroids and choose the right treatment. 

Limited attention on fibroids in both society and the medical community means that at-risk women do not have access to the information they need about the disease. A recent study in the Journal of Women’s Health found that only 49% of “at-risk” women, those who had symptoms suggestive of fibroids but not a clinical diagnosis, had heard of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women receive a fibroid diagnosis, their treatment options are limited and often affect their fertility. To relieve pain associated with uterine fibroids, women can take over-the-counter acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), but these are just temporary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don’t work for all women and are not an option for women trying to get pregnant.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com